

Benefits and challenges of biomarker studies for oncology drug development

Trends in biomarker studies

What do you believe to be the most commonly used biomarker type in oncology today?



Which type of biomarkers do you currently use in your studies?



What do you use biomarker assays for in your studies?



Which type of cancer could benefit the most from biomarker studies?



Which platforms do you use for your biomarker assays?

37%	Meso Scale Discovery	(MSD)
34%	LC–MS/MS	
29%	Conventional ELISA	
22%	Quanterix Simoa™ HD-X/SR-X/SP-X	
22%	Olink	
22%	qPCR	
21%	ddPCR	
20%	GC-MS	
18%	ICP-MS	
18%	Gyros Workstation	
15%	Luminex Magpix	
15%	NGS	
14%	Protein Simple Ella	
12%	Flow cytometry	

What do you consider to be the main benefits of biomarker assays supporting drug development for oncology?

41%

43%

31%



What percentage of your work involves precision medicine?



What do you think are the main challenges of implementing precision medicine practices in oncology?



Demographics



Organization	Job title
Academic 8%	Business Development Director
Not-for-profit	Consultant 14%
CRO CDMO	Department Head
Diagnostics 8%	Lecturer
Environmental Industrial	Process Engineer
Government NGO 7%	Product Manager 10%
Hospital Clinic 8%	Professor 9%
Pharma Biotech 33%	Research Director
Private Research Foundation 5%	Scientist 21%
Vendor Manufacturer 3%	Student 7%

This infographic has been created as part of a Bioanalysis Zone feature in association with Frontage.



